Abstract
Gastric cancer is still a major cancer worldwide. The early diagnosis rate of gastric cancer in most high incidence countries is low. At present, the overall treatment effect of gastric cancer is poor, and the median overall survival remains low. Most of the patients with gastric cancer are in an advanced stage when diagnosed, and drug treatment has become the main means. Thus, new targeted drugs and therapeutic strategies are the hope of improving the therapeutic effect of gastric cancer. In this review, we summarize the new methods and advances of targeted therapy for gastric cancer, including novel molecular targeted therapeutic agents and drug delivery systems, with a major focus on the development of drug delivery systems (drug carriers and targeting peptides). Elaborating these new methods and advances will contribute to the management of gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abak A, Abhari A, Rahimzadeh S (2018) Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics. PeerJ 6:e4763. https://doi.org/10.7717/peerj.4763
Allahverdiyev AM, Parlar E, Dinparvar S, Bagirova M, Abamor EŞ (2018) Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects. Artif Cells Nanomed Biotechnol 46:S755–S762
Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380. https://doi.org/10.1126/science.279.5349.377
Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697
Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–252. https://doi.org/10.1016/s0022-2836(65)80093-6
Becerra C et al (2015) Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 33:1. https://doi.org/10.1200/jco.2015.33.15_suppl.4069
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D (2016) Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30:836–848
Bonelli P et al (2012) Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations. Int J Nanomedicine 7:5683–5691. https://doi.org/10.2147/IJN.S34723
Brahmer JR et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175. https://doi.org/10.1200/jco.2009.26.7609
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics. https://doi.org/10.3390/pharmaceutics9020012
Chen B et al (2009) A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol 10:63. https://doi.org/10.1186/1471-2121-10-63
Chen K et al (2012a) Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol 14:96–105. https://doi.org/10.1007/s11307-011-0479-1
Chen K et al (2012b) A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. Amino Acids 42:1329–1337. https://doi.org/10.1007/s00726-010-0827-5
Chen Y, Sun L, Guo D, Wu Z, Chen W (2017) Co-delivery of hypoxia inducible factor-1alpha small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells. J Gene Med. https://doi.org/10.1002/jgm.2998
Chen H et al (2018) Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein. Int J Nanomedicine 13:5347–5359. https://doi.org/10.2147/IJN.S165109
Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronfleh MW (2019) Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 23:20. https://doi.org/10.1186/s40824-019-0166-x
Chereddy KK, Payen VL, Preat V (2018) PLGA: from a classic drug carrier to a novel therapeutic activity contributor. J Control Release 289:10–13. https://doi.org/10.1016/j.jconrel.2018.09.017
Chu DS, Bocek MJ, Shi J, Ta A, Ngambenjawong C, Rostomily RC, Pun SH (2015) Multivalent display of pendant pro-apoptotic peptides increases cytotoxic activity. J Control Release 205:155–161. https://doi.org/10.1016/j.jconrel.2015.01.013
Colombo M, Raposo G, Théry C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30:255–289
Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107:459–466. https://doi.org/10.1002/cncr.22035
Das M, Huang L (2019) Liposomal nanostructures for drug delivery in gastrointestinal cancers. J Pharmacol Exp Ther 370:647–656. https://doi.org/10.1124/jpet.118.254797
Ding N et al (2019) iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun 10:1336. https://doi.org/10.1038/s41467-019-09296-6
Ellerby HM et al (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032–1038. https://doi.org/10.1038/12469
Fang RH et al (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14:2181–2188. https://doi.org/10.1021/nl500618u
Fang J et al (2018) Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. Int J Nanomedicine 13:5113–5126. https://doi.org/10.2147/IJN.S170862
Fang Z, Li X, Xu Z, Du F, Wang W, Shi R, Gao D (2019) Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery. Int J Nanomedicine 14:5785–5797. https://doi.org/10.2147/IJN.S213974
Fernandes E et al (2019) Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm 570:118646. https://doi.org/10.1016/j.ijpharm.2019.118646
Fitts CA, Ji N, Li YS, Tan C (2019) Exploiting exosomes in cancer liquid biopsies and drug delivery. Adv Healthc Mater 8:e1801268. https://doi.org/10.1002/adhm.201801268
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186. https://doi.org/10.1056/NEJM197111182852108
Fuchs CS et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39. https://doi.org/10.1016/s0140-6736(13)61719-5
Fuchs CS et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013. https://doi.org/10.1001/jamaoncol.2018.0013
Gu J, Li X, Li H, Jin Z, Jin J (2019) MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer. Biosci Rep. https://doi.org/10.1042/bsr20181258
Han B, Yang Y, Chen J, He X, Lv N, Yan R (2019) PRSS23 knockdown inhibits gastric tumorigenesis through EIF2 signaling. Pharmacol Res 142:50–57. https://doi.org/10.1016/j.phrs.2019.02.008
He XW, Liu T, Chen YX, Cheng DJ, Li XR, Xiao Y, Feng YL (2008) Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther 15:193–202. https://doi.org/10.1038/sj.cgt.7701122
Hecht JR et al (2016) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC–a randomized phase III trial. J Clin Oncol 34:443–451. https://doi.org/10.1200/jco.2015.62.6598
Hong C et al (2019) Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer. Theranostics 9:4437–4449. https://doi.org/10.7150/thno.34953
Hu Y, Wang Z, Qiu Y, Liu Y, Ding M, Zhang Y (2019) Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma. J Drug Target 27:1135–1143. https://doi.org/10.1080/1061186X.2019.1610766
Huang H, Liao W, Zhu X, Liu H, Cai L (2017a) Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer. Biomed Pharmacother 92:562–568. https://doi.org/10.1016/j.biopha.2017.05.088
Huang Y, Li X, Sha H, Zhang L, Bian X, Han X, Liu B (2017b) sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment. Sci Rep 7:579. https://doi.org/10.1038/s41598-017-00688-6
Huang Y, Li X, Sha H, Zhang L, Bian X, Han X, Liu B (2017c) Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy. Oncol Rep 37:2063–2070. https://doi.org/10.3892/or.2017.5440
Hui X et al (2008) Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release 131:86–93. https://doi.org/10.1016/j.jconrel.2008.07.024
Huo J (2016) Effects of chitosan nanoparticle-mediated BRAF siRNA interference on invasion and metastasis of gastric cancer cells. Artif Cells Nanomed Biotechnol 44:1232–1235. https://doi.org/10.3109/21691401.2015.1019666
Ji RB et al (2019) MiR-374a-5p: a new target for diagnosis and drug resistance therapy in gastric cancer. Mol Ther Nucleic Acids 18:320–331
Jiang X, Chan HC (2012) Magnetic nanoparticles for treatment of gastric cancer. J Gastroenterol Hepatol 27:191–193. https://doi.org/10.1111/j.1440-1746.2011.07031.x
Jiang L et al (2018) MicroRNA-623 targets cyclin D1 to inhibit cell proliferation and enhance the chemosensitivity of cells to 5-fluorouracil in gastric cancer. Oncol Res 27:19–27. https://doi.org/10.3727/096504018x15193469240508
Jin Z et al (2018) A tumor-specific tissue-penetrating peptide enhances the efficacy of chemotherapy drugs in gastric cancer Yonsei. Med J 59:595–601. https://doi.org/10.3349/ymj.2018.59.5.595
Kang J et al (2013) A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells. Cancer Lett 339:247–259. https://doi.org/10.1016/j.canlet.2013.06.016
Kang YK et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471. https://doi.org/10.1016/s0140-6736(17)31827-5
Karuppaiya P, Satheeshkumar E, Tsay HS (2019) Biogenic synthesis of silver nanoparticles using rhizome extract of Dysosma pleiantha and its antiproliferative effect against breast and human gastric cancer cells. Mol Biol Rep 46:4725–4734. https://doi.org/10.1007/s11033-019-04917-1
Kennedy PJ et al (2018) Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. Acta Biomater 81:208–218. https://doi.org/10.1016/j.actbio.2018.09.043
Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048–10056. https://doi.org/10.1158/0008-5472.CAN-06-1605
Kubota T et al (2018) HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer. Nanomedicine 14:1919–1929. https://doi.org/10.1016/j.nano.2018.05.019
Lai CK et al (2014) Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. Nanomedicine (Lond) 9:803–817. https://doi.org/10.2217/nnm.13.54
Lazar DC, Taban S, Cornianu M, Faur A, Goldis A (2016) New advances in targeted gastric cancer treatment. World J Gastroenterol 22:6776–6799. https://doi.org/10.3748/wjg.v22.i30.6776
Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC (2007) Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67:10958–10965. https://doi.org/10.1158/0008-5472.CAN-07-2233
Lei Z et al (2018) Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer. Cell Death Dis 9:579. https://doi.org/10.1038/s41419-018-0594-x
Li ZJ, Cho CH (2012) Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med 10(Suppl 1):S1. https://doi.org/10.1186/1479-5876-10-S1-S1
Li Y, Qin C (2019) MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1. Hum Cell 32:352–359. https://doi.org/10.1007/s13577-019-00244-6
Li ZJ et al (2010) A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Control Release 148:292–302. https://doi.org/10.1016/j.jconrel.2010.09.015
Li W et al (2012) Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 33:5349–5362. https://doi.org/10.1016/j.biomaterials.2012.04.016
Li Y et al (2013) Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells. Bioconjug Chem 24:133–143. https://doi.org/10.1021/bc300537z
Li C et al (2014) Cytotoxicity of ultrafine monodispersed nanoceria on human gastric cancer cells. J Biomed Nanotechnol 10:1231–1241. https://doi.org/10.1166/jbn.2014.1863
Li C et al (2015a) Human induced pluripotent stem cells labeled with fluorescent magnetic nanoparticles for targeted imaging and hyperthermia therapy for gastric cancer. Cancer Biol Med 12:163–174. https://doi.org/10.7497/j.issn.2095-3941.2015.0040
Li QE et al (2015b) Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol 36:2007–2012
Li X et al (2015c) D-SP5 peptide-modified highly branched polyethylenimine for gene therapy of gastric adenocarcinoma. Bioconjug Chem 26:1494–1503. https://doi.org/10.1021/acs.bioconjchem.5b00137
Li Y et al (2015d) Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A 112:1839–1844. https://doi.org/10.1073/pnas.1424171112
Li J et al (2016) Randomized, double-blind, placebo-controlled phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454. https://doi.org/10.1200/jco.2015.63.5995
Li C, Wang Y, Zhang H, Li M, Zhu Z, Xue Y (2019) An investigation on the cytotoxicity and caspase-mediated apoptotic effect of biologically synthesized gold nanoparticles using Cardiospermum halicacabum on AGS gastric carcinoma cells. Int J Nanomedicine 14:951–962. https://doi.org/10.2147/IJN.S193064
Liang S et al (2006) Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med (Berl) 84:764–773. https://doi.org/10.1007/s00109-006-0064-2
Lin YH, Chen ZR, Lai CH, Hsieh CH, Feng CL (2015) Active Targeted nanoparticles for oral administration of gastric cancer therapy. Biomacromol 16:3021–3032. https://doi.org/10.1021/acs.biomac.5b00907
Lin LY et al (2018) Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer 17:84
Liu B et al (2009) Adenovirus vector-mediated upregulation of spermidine /spermine N1-acetyltransferase impairs human gastric cancer growth in vitro and in vivo. Cancer Sci 100:2126–2132. https://doi.org/10.1111/j.1349-7006.2009.01290.x
Liu R et al (2014a) The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases. J Mol Med (Berl) 92:165–175. https://doi.org/10.1007/s00109-013-1093-2
Liu X et al (2014b) A visualized investigation at the atomic scale of the antitumor effect of magnetic nanomedicine on gastric cancer cells. Nanomedicine (Lond) 9:1389–1402. https://doi.org/10.2217/nnm.13.142
Liu F, Bu ZY, Zhao F, Xiao DP (2018) Increased T-helper 17 cell differentiation mediated by exosome-mediated micro RNA-451 redistribution in gastric cancer infiltrated T cells. Cancer Sci 109:65–73
Liu TS et al (2019a) Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun 39:10. https://doi.org/10.1186/s40880-019-0384-6
Liu Z, Ran H, Wang Z, Zhou S, Wang Y (2019ab) Targeted and pH-facilitated theranostic of orthotopic gastric cancer via phase-transformation doxorubicin-encapsulated nanoparticles enhanced by low-intensity focused ultrasound (LIFU) with reduced side effect. Int J Nanomedicine 14:7627–7642. https://doi.org/10.2147/IJN.S212888
Lu TX, Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141:1202–1207. https://doi.org/10.1016/j.jaci.2017.08.034
Lu L et al (2017) A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFalpha to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil. Peptides 97:54–63. https://doi.org/10.1016/j.peptides.2017.09.020
Ma H, Liu Y, Shi M, Shao X, Zhong W, Liao W, Xing MM (2015) Theranostic, pH-responsive, doxorubicin-loaded nanoparticles inducing active targeting and apoptosis for advanced gastric cancer. Biomacromol 16:4022–4031. https://doi.org/10.1021/acs.biomac.5b01039
Mao B et al (2018) Cyclic cRGDfk peptide and Chlorin e6 functionalized silk fibroin nanoparticles for targeted drug delivery and photodynamic therapy. Biomaterials 161:306–320. https://doi.org/10.1016/j.biomaterials.2018.01.045
Matsumura Y, Yokoyama M, Kataoka K, Okano T, Sakurai Y, Kawaguchi T, Kakizoe T (1999) Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 90:122–128. https://doi.org/10.1111/j.1349-7006.1999.tb00675.x
Mohammadian F, Pilehvar-Soltanahmadi Y, Mofarrah M, Dastani-Habashi M, Zarghami N (2016) Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. Artif Cells Nanomed Biotechnol 44:1972–1978. https://doi.org/10.3109/21691401.2015.1129615
Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H (2015) Silk fibroin nanoparticle as a novel drug delivery system. J Control Release 206:161–176. https://doi.org/10.1016/j.jconrel.2015.03.020
Mousavi B, Tafvizi F, Zaker Bostanabad S (2018) Green synthesis of silver nanoparticles using Artemisia turcomanica leaf extract and the study of anti-cancer effect and apoptosis induction on gastric cancer cell line (AGS). Artif Cells Nanomed Biotechnol 46:499–510. https://doi.org/10.1080/21691401.2018.1430697
Muller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 50:161–177. https://doi.org/10.1016/s0939-6411(00)00087-4
Muntimadugu E, Kommineni N, Khan W (2017) Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol Res 126:109–122. https://doi.org/10.1016/j.phrs.2017.05.010
Nakajima TE et al (2008) Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res 68:9318–9322. https://doi.org/10.1158/0008-5472.CAN-08-2822
Ohtsu A et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976. https://doi.org/10.1200/jco.2011.36.2236
Ohtsu A et al (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31:3935–3943. https://doi.org/10.1200/jco.2012.48.3552
Pan HM, Lang WY, Yao LJ, Wang Y, Li XL (2019) shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway. World J Gastrointest Oncol 11:622–633. https://doi.org/10.4251/wjgo.v11.i8.622
Pavlakis N et al (2016) Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol 34:2728–2735. https://doi.org/10.1200/jco.2015.65.1901
Qi LF, Xu ZR, Li Y, Jiang X, Han XY (2005) In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol 11:5136–5141. https://doi.org/10.3748/wjg.v11.i33.5136
Ruan J, Ji J, Song H, Qian Q, Wang K, Wang C, Cui D (2012) Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer. Nanoscale Res Lett 7:309. https://doi.org/10.1186/1556-276X-7-309
Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, de Almeida LP (2017) Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release 262:247–258
Salehi S, Shandiz SA, Ghanbar F, Darvish MR, Ardestani MS, Mirzaie A, Jafari M (2016) Phytosynthesis of silver nanoparticles using Artemisia marschalliana Sprengel aerial part extract and assessment of their antioxidant, anticancer, and antibacterial properties. Int J Nanomedicine 11:1835–1846. https://doi.org/10.2147/IJN.S99882
Satoh T et al (2015) Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer 18:824–832. https://doi.org/10.1007/s10120-014-0420-9
Selim JH, Shaheen S, Sheu WC, Hsueh CT (2019a) Targeted and novel therapy in advanced gastric cancer. Exp Hematol Oncol 8:25. https://doi.org/10.1186/s40164-019-0149-6
Selim JH, Shaheen S, Sheu WC, Hsueh CT (2019b) Targeted and novel therapy in advanced gastric cancer. Exp Hematol Oncol 8:23. https://doi.org/10.1186/s40164-019-0149-6
Sha H et al (2015a) A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo. Eur J Pharm Sci 77:60–72. https://doi.org/10.1016/j.ejps.2015.05.020
Sha H et al (2015b) Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release 200:188–200. https://doi.org/10.1016/j.jconrel.2014.12.039
Shi YT et al (2019) Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer. Int J Biol Clin Oncol 25:89–99
Shitara K et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437–1448. https://doi.org/10.1016/s1470-2045(18)30739-3
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317. https://doi.org/10.1126/science.4001944
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480. https://doi.org/10.1038/nrc2394
Sugahara KN et al (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510–520. https://doi.org/10.1016/j.ccr.2009.10.013
Taghavi S, Nia AH, Abnous K, Ramezani M (2017) Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells. Int J Pharm 516:301–312. https://doi.org/10.1016/j.ijpharm.2016.11.027
Takimoto R et al (2017) Efficacy of adoptive immune-cell therapy in patients with advanced gastric cancer: a retrospective study. Anticancer Res 37:3947–3954. https://doi.org/10.21873/anticanres.11778
Tanaka T et al (2006) Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 12:3803–3813. https://doi.org/10.1158/1078-0432.CCR-06-0024
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 106:16157–16162. https://doi.org/10.1073/pnas.0908201106
Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (2007) Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 98:779–789. https://doi.org/10.1111/j.1349-7006.2007.00477.x
Trams EG, Lauter CJ, Salem JN, Heine U (1981) Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta 645:63–70
Wang H et al (2014a) Selection and characterization of a peptide specifically targeting to gastric cancer cell line SGC-7901 using phage display. Int J Pept Res Ther 20:87–94
Wang J, Zhu R, Sun X, Zhu Y, Liu H, Wang SL (2014b) Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. Int J Nanomedicine 9:3987–3998. https://doi.org/10.2147/IJN.S64103
Wang JJ, Wang ZY, Chen R, Xiong J, Yao YL, Wu JH, Li GX (2015a) Macrophage-secreted exosomes delivering miRNA-21 inhibitor can regulate BGC-823 cell proliferation. Asian Pac J Cancer Prev 16:4203–4209
Wang W et al (2015b) RGD peptides-conjugated pluronic triblock copolymers encapsulated with AP-2alpha expression plasmid for targeting gastric cancer therapy in vitro and in vivo. Int J Mol Sci 16:16263–16274. https://doi.org/10.3390/ijms160716263
Wang X et al (2015c) Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. BMC Cancer 15:358. https://doi.org/10.1186/s12885-015-1361-3
Wang XY et al (2018) Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther 26:774–783
Wang M, Yu F, Ding H, Wang Y, Li PF, Wang K (2019) Emerging function and clinical values of exosomal micrornas in cancer. Mol Ther Nucleic Acids 16:791–804
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:16014. https://doi.org/10.1038/natrevmats.2016.14
Wilke H et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. https://doi.org/10.1016/s1470-2045(14)70420-6
Wrzesinski C et al (2010) Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33:1–7. https://doi.org/10.1097/CJI.0b013e3181b88ffc
Wu P et al (2013) Facile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug delivery. ACS Appl Mater Interfaces 5:12638–12645. https://doi.org/10.1021/am403992b
Wu Y, Zhang Q, Ruan Z, Yin Y (2016) Intrinsic effects of gold nanoparticles on proliferation and invasion activity in SGC-7901 cells. Oncol Rep 35:1457–1462. https://doi.org/10.3892/or.2015.4474
Xiao YF et al (2016) Cerium oxide nanoparticles inhibit the migration and proliferation of gastric cancer by increasing DHX15 expression. Int J Nanomedicine 11:3023–3034. https://doi.org/10.2147/IJN.S103648
Xin J et al (2013) In vivo gastric cancer targeting and imaging using novel symmetric cyanine dye-conjugated GX1 peptide probes. Bioconjug Chem 24:1134–1143. https://doi.org/10.1021/bc3006539
Xiong D et al (2015) GX1-mediated anionic liposomes carrying adenoviral vectors for enhanced inhibition of gastric cancer vascular endothelial cells. Int J Pharm 496:699–708. https://doi.org/10.1016/j.ijpharm.2015.11.019
Yang F et al (2014) Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. Febs J 281:802–813. https://doi.org/10.1111/febs.12625
Yang Z et al (2016) Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. Nanoscale 8:11543–11558. https://doi.org/10.1039/c6nr01749e
Yao HJ, Zhang YG, Sun L, Liu Y (2014) The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials 35:9208–9223. https://doi.org/10.1016/j.biomaterials.2014.07.033
Yi JH et al (2012) Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 106:1469–1474. https://doi.org/10.1038/bjc.2012.100
Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15:541–555. https://doi.org/10.1038/nrg3763
Yingchoncharoen P, Kalinowski DS, Richardson DR (2016) Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev 68:701–787. https://doi.org/10.1124/pr.115.012070
Yoon JH et al (2018) Gastrokine 1 protein is a potential theragnostic target for gastric cancer. Gastric Cancer 21:956–967
Yoshida M et al (2010) Feasibility of chemohyperthermia with docetaxel-embedded magnetoliposomes as minimally invasive local treatment for cancer. Int J Cancer 126:1955–1965. https://doi.org/10.1002/ijc.24864
Yoshida M et al (2012) Tumor local chemohyperthermia using docetaxel-embedded magnetoliposomes: Interaction of chemotherapy and hyperthermia. J Gastroenterol Hepatol 27:406–411. https://doi.org/10.1111/j.1440-1746.2011.06972.x
Zhang WJ et al (2012) Affinity peptide developed by phage display selection for targeting gastric cancer. World J Gastroenterol 18:2053–2060. https://doi.org/10.3748/wjg.v18.i17.2053
Zhang J et al (2013) Targeted radiotherapy with tumor vascular homing trimeric GEBP11 peptide evaluated by multimodality imaging for gastric cancer. J Control Release 172:322–329. https://doi.org/10.1016/j.jconrel.2013.08.033
Zhang D et al (2015) A CD44 specific peptide developed by phage display for targeting gastric cancer. Biotechnol Lett 37:2311–2320. https://doi.org/10.1007/s10529-015-1896-z
Zhang L, Xing Y, Gao Q, Sun X, Zhang D, Cao G (2017) Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother 93:1136–1143. https://doi.org/10.1016/j.biopha.2017.06.103
Zhang HY et al (2018) Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor si RNA. Cancer Sci 109:629–641
Zhang E, Xing R, Liu S, Li K, Qin Y, Yu H, Li P (2019a) Vascular targeted chitosan-derived nanoparticles as docetaxel carriers for gastric cancer therapy. Int J Biol Macromol 126:662–672. https://doi.org/10.1016/j.ijbiomac.2018.12.262
Zhang J, Zhao D, Li Q, Du X, Liu Y, Dai X, Hong L (2019b) Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT. Cancer Manag Res 11:4481–4491. https://doi.org/10.2147/cmar.S186649
Zhang Z et al (2019c) Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/beta-catenin oncogenic pathways. Mol Carcinog 58:1450–1464. https://doi.org/10.1002/mc.23027
Zhao R et al (2018) Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer 17:68
Zhi M et al (2004) Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer. Cancer Biol Ther 3:1232–1235. https://doi.org/10.4161/cbt.3.12.1223
Zhu A et al (2018) Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer. Am J Cancer Res 8:91–105
Acknowledgements
This work was supported by the grants from the National Natural Science Foundation of China (81960444) and the Science and Technology Program of Health Commission of Jiangxi Province of China (20121020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jiang, L., Gong, X., Liao, W. et al. Molecular targeted treatment and drug delivery system for gastric cancer. J Cancer Res Clin Oncol 147, 973–986 (2021). https://doi.org/10.1007/s00432-021-03520-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03520-x